Sartorius (FRA:SRT3) received a €130.00 ($151.16) target price from investment analysts at Hauck & Aufhaeuser in a research report issued to clients and investors on Thursday, April 4th, Borsen Zeitung reports. The brokerage presently has a “sell” rating on the stock. Hauck & Aufhaeuser’s target price indicates a potential downside of 19.50% from the company’s current price.
A number of other research analysts also recently issued reports on SRT3. Kepler Capital Markets set a €107.00 ($124.42) target price on shares of Sartorius and gave the company a “sell” rating in a research report on Tuesday, January 29th. UBS Group set a €142.00 ($165.12) price target on Sartorius and gave the company a “buy” rating in a research note on Thursday, December 13th. Warburg Research set a €141.00 ($163.95) price target on Sartorius and gave the company a “buy” rating in a research note on Tuesday, January 29th. Berenberg Bank set a €115.00 ($133.72) target price on Sartorius and gave the stock a “sell” rating in a research note on Friday, February 22nd. Finally, HSBC set a €116.00 ($134.88) target price on Sartorius and gave the stock a “neutral” rating in a research note on Tuesday, February 5th. Five research analysts have rated the stock with a sell rating and four have issued a hold rating to the company. The company has an average rating of “Sell” and an average target price of €126.61 ($147.22).
SRT3 stock traded up €1.40 ($1.63) on Thursday, reaching €161.50 ($187.79). 51,322 shares of the company were exchanged. Sartorius has a 12 month low of €71.00 ($82.56) and a 12 month high of €124.70 ($145.00).
Sartorius Aktiengesellschaft supplies pharmaceutical and laboratory equipment worldwide. It operates in two divisions, Bioprocess Solutions, and Lab Products & Services. The company offers products for suspension cell analysis and live-cell analysis inside incubator for oncology, immuno-oncology, antibody discovery, neuroscience, and stem cell research; cell culture media, including antibody and recombinant protein, viral vaccines, and regenerative medicine media, as well as general media and downstream buffers; and multi-parallel, single-use, benchtop, stainless steel, microbial, and cell culture bioreactors, as well as cell culture expansion systems and software applications for bioreactors.
Featured Article: What is a Leveraged Buyout (LBO)?
Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with MarketBeat.com's FREE daily email newsletter.